IHC-IDH 1

The IHC – IDH1 test is a specialized immunohistochemistry (IHC) diagnostic test used to detect Isocitrate Dehydrogenase 1 (IDH1) mutation protein expression in tissue samples. IDH1 is an important molecular marker widely used in the diagnosis and classification of brain tumors, especially gliomas.

Mutations in the IDH1 gene are commonly seen in certain diffuse gliomas, astrocytomas, oligodendrogliomas, and secondary glioblastomas. Detecting the IDH1 mutation helps pathologists classify brain tumors more accurately and provides valuable prognostic information.

The presence of an IDH1 mutation is generally associated with a better prognosis and improved treatment response compared to IDH1-wildtype tumors. This makes the test highly valuable for personalized treatment planning and modern neuro-oncology management.

The IDH1 IHC test is often performed alongside other brain tumor markers such as ATRX, p53, Ki-67, and GFAP for comprehensive tumor characterization.

Benefits of the Test

The IDH1 test offers several important clinical benefits:

• Detects IDH1 mutation protein expression
• Supports accurate glioma classification
• Helps distinguish glioma subtypes
• Provides important prognostic information
• Assists in personalized treatment planning
• Supports modern molecular brain tumor diagnosis

This test is essential for accurate neuro-oncology evaluation.

Why Doctors Recommend This Test

Doctors recommend the IDH1 test when brain tumors are suspected or when detailed glioma classification is required.

It is commonly advised for:

• Suspected glioma diagnosis
• Brain tumor subtype classification
• Differentiation of primary and secondary glioblastoma
• Molecular characterization of CNS tumors
• Precision neuro-oncology treatment planning

The results help neurologists, oncologists, and neurosurgeons select appropriate therapy strategies.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected brain tissue biopsy or surgical tumor specimens.

Normal Reporting Time

The usual turnaround time for the IDH1 IHC test is 3 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients diagnosed with brain tumors
• Individuals suspected of glioma
• Patients requiring CNS tumor classification
• Cases needing molecular pathology confirmation
• Neuro-oncology patients requiring personalized treatment planning

The IHC IDH1 test is a critical diagnostic tool in modern neuro-pathology. It enables precise brain tumor classification, provides prognostic insight, and helps guide effective treatment decisions for improved patient outcomes.